Francis deSouza, Illumina CEO (Photographer: Kyle Grillot/Bloomberg via Getty Images)
February 8, 2023 09:22 AM ESTUpdated 09:40 AM
Pharma

Af­ter a bad quar­ter, Il­lu­mi­na fo­cus­es on new DNA se­quenc­ing plat­form

Jared Whitlock

Features Editor

Il­lu­mi­na on Tues­day re­port­ed a steep drop in quar­ter­ly rev­enue and in 2022, the com­pa­ny took a charge of $3.91 bil­lion to write down the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times